Discontinuation of Infliximab May Cause Relapse of Ulcerative Colitis

Article

Restarting infliximab after discontinuation can still be effective in ulcerative colitis, however.

Discontinuing infliximab can lead to a relapse in patients with ulcerative colitis.

Reporting at Digestive Disease Week 2016, researchers gave the results of a study of 161 ulcerative colitis patients from 12 centers in Europe and 1 in Israel.

All discontinued infliximab after 12 months and were then treated either with thiopurines, 5-ASA, thiopurines and 5-ASA, other therapies, or no therapy.

Another group of 69 patients continued on inflixmab. Median follow-up was at 39 months.

Through 12 months after discontinuation, 28 of 92 patients (30.4%) had a disease flare-up compared with 6% in the control group.

In patients who started infliximab, clinical response and remission were 71.4% and 50% respectively.

At last follow-up, 41% of patients who discontinued infliximab vs. 21.5% in the control group had a flare-up. Hospitalizations for ulcerative colitis were seen in 5% and 3% of patients, respectively, at last follow-up.

The team concluded "infliximab withdrawal for prolonged remission was associated with a higher risk for relapse in UC patients, but not with adverse events, hospitalization of colectomy.”

Restarting infliximab after discontinuation was effective in 71% of the patients, and safe, they wrote.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Video 12 - "Collaborative Care: Key Stakeholders in HE Treatment and Recovery"
Video 11 - "Optimizing Transitions of Care for Hepatic Encephalopathy Patients"
Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"
Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"
Video 6 - "evaluating CDK4/6 inhibitor safety profiles"
Video 5 - "CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC"
Video 8 - "Challenges of Concurrent Administration: RSV and Other Vaccines "
© 2024 MJH Life Sciences

All rights reserved.